Career Exploration Elective in Hematology Oncology
Title of Clerkship: M3 Career Exploration Elective in Hematology Oncology
Elective Year(s): Third-Year
Department: Internal Medicine
Type of Elective: Clinical
Clerkship Site: UTMC
Course Number: MEDI 602
Elective Description/ Requirements:
This course is designed to give M3 students the opportunity to explore their career
expectations, comparing and contrasting these with a career in Hematology Oncology.
M3 students will spend approximately 2 weeks experiencing the elements of a career in Hematology Oncology. Students will be incorporated into the team, allowing a closer investigation of the student’s’ career expectations including work hours, work settings, required tasks, and work-life balance. Students should reflect on how their career goals parallel the expectations and demands of a career in Hematology Oncology.
Length of Clerkship: 2 weeks
Educational Course Objectives and Links to EPOs:
- Describe their own expectations with regard to the career expectation process and discuss that process with a career advisor. (EPOs: PBL-1, PBL-3)
- Demonstrate interest in the career exploration process and discuss how their skills and interests align with the potential specialty choice. (EPOs: PBL-1, PBL-3)
- Explain work hours, work tasks, settings, salary, job outlook and work-life balance corresponding to specialties they are considering. (EPOs: PB-2)
Professionalism: Students will meet or exceed the institutional standards for professionalism as stated in the current Educational Program Objectives and the current Educational Course Objectives for the Sponsoring Department.
Instructional Methods:
- Independent Learning
- Mentorship
- Reflection
- Ward rounds
- Clinical Experience (ambulatory and/or inpatient)
Evaluation Methods:
- Attendance
- Participation
- Written Reflection
Prerequisites: None
Clerkship Director: Mani Askari, M.D.
Clerkship Coordinator: Dawn Jagodzinski; Mackenzie McNair
Phone Number: 419-383-5022
Email: Dawn.jagodzinski@utoledo.edu
Special Requirements: None
ECC Approved
January 2024